(Renal Cancer) Is Tivozanib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 9, 2020
- Reading time: 2 minutes
On December 3, 2019, Brian I Rini published in The Lancet Oncology the Phase 3 TIVO-3 trial results evaluating the VEGF inhibitor tivozanib monotherapy as 3rd/4th-line treatment in renal cell carcinoma (RCC) patients.
Trial Design
This Phase 3 trial randomized RCC patients with at least two prior lines of therapy in a 1:1 ratio to:
- Tivozanib monotherapy group (N=175)
- Sorafenib monotherapy group (N=175)
Primary endpoint: Progression-free survival (PFS).
Background: Multiple clinical trials had previously established the efficacy of VEGF inhibitors in RCC, including in patients with prior anti-PD-1 antibody treatment. This trial was designed to evaluate tivozanib monotherapy in this setting.
Efficacy Results
At a median follow-up of 19.0 months:
- Median PFS: Tivozanib 19.0 months / Sorafenib 3.9 months
- Tivozanib significantly reduced progression risk by 27% (HR 0.73)
Safety Profile
Most common Grade 3–4 adverse events:
- Hypertension: Tivozanib 20% / Sorafenib 14%
Serious adverse event rates:
- Tivozanib: 11% / Sorafenib: 10%
No treatment-related deaths were reported.
Conclusions
Based on TIVO-3 results, Brian I Rini concluded that tivozanib monotherapy as 3rd/4th-line treatment significantly improved PFS compared to sorafenib in RCC patients, with good tolerability.
Source: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2019 Dec 3. doi: 10.1016/S1470-2045(19)30735-1.
Tags: #RenalCancer #Tivozanib
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4